HomeTrading IdeasH2 2025: Room for...

H2 2025: Room for Optimism, Risk for Complacency

Reasons To Be Fearful, Reasons To Be Cheerful

It was an eventful first half of the year, to say the least…

In January, the rise of DeepSeek was a wake-up call for the world, demonstrating that China is a major competitor to the US in AI and technology. The new US administration rapidly reordered geopolitical and economic relationships, implementing aggressive trade policies and tariffs.

On April 2, 2025—a date President Donald Trump proclaimed “Liberation Day”—the US administration announced the most sweeping tariff hike since the 1930s. This took the world (and markets) by surprise and led to retaliatory measures, fears of a global trade conflict, and financial markets turmoil. However, the US administration, under the pressure of the US Treasury market, decided to scale back on some of their plans. In early May, after talks in Geneva, China and the US agreed to lower tariffs, triggering a relief rally in financial markets.

On the geopolitical front, Russia’s war in Ukraine continued with no resolution in sight. NATO leaders agreed to increase defence spending to 5% of GDP in June 2025, signalling heightened concerns about Russia’s belligerence. The Israel-Iran conflict escalated, with a US bombing of Iran’s nuclear sites reported on June 23, 2025, injecting uncertainty into global markets and inflation outlooks.

The combination of trade tensions, geopolitical conflicts, and policy shifts created a volatile environment for financial markets. It is, however, remarkable to see the MSCI all Country index and the both hitting a new all time high by the end of June. The resilience of earnings and the economy, coupled with the retro-pedalling by the US on tariffs, helped financial markets to record strong gains during the second quarter.

Still, the biggest loser of this first half of the year is the dollar. Another major development has been a shift in performance leadership with international equity markets, value style and emerging markets debt outperforming US equity markets, growth style, and US bonds. As in 2024, gold remains the best-performing traditional asset class.

As we enter the second half of 2025, what lies ahead? We believe there are reasons to be fearful, but also reasons to be cheerful.

The Downside Risks

Tariffs are paused, not removed — we’re not out of the woods. The 90-day pause ends in July, China’s lower tariffs expire in August, and both collide with the US debt-ceiling showdown. We expect volatility to remain elevated.

Rising global bond yields are another concern — pushing up mortgage rates, pressuring equity valuations, and threatening a carry trade unwind.

And geopolitical risks remain high, with tensions and conflicts ongoing in the Middle East and Ukraine.

Reasons To Be Cheerful

In the US, lower tariffs, lower taxes and lower rates could become the investors playbook for the second half of the year.

A trade deal with Europe and Japan looks likely, with some easing on China also possible.

In the US, the One, Big Beautiful Bill could pave the way for tax cuts.

Inflation is easing, giving the Federal Reserve room to . There is also room for the ECB to lower rates.

First quarter earnings beat expectations. Profits remained resilient, with companies holding on to staff and already approved capital spending.

In this context, G7 economies should avoid a recession.

How Do You Position Portfolios Amid Global Uncertainty?

Overall, in this environment, we believe bouts of volatility can be used as opportunities to add quality investments at better prices. We continue to favour diversification and broadening leadership as key investment themes. Peak trade tensions and volatility may be behind us, but don’t expect a smooth ride till the end of the year.

Our main recommendations to investors are the following:

First, stay invested, timing the market is risky. Those who tried to time the market in April and sold at the trough realised losses and were underinvested during the rebound.

Two, keep some international diversification, but US exceptionalism is NOT dead. The strongest companies are US-listed, tariffs and a weaker dollar also pressure regions like Europe.

Three, focus on quality and diversify across styles, sectors, and asset classes.

To Conclude, Here Are Our Top Investment Themes

Artificial Intelligence.  Lower AI costs will drive adoption. Which stocks are going to benefit? Software firms and companies building AI infrastructure.

Innovation beyond the Magnificent 7. Disruption is everywhere: robotics, autonomous vehicles, cybersecurity. And it’s global. DeepSeek shows China is a serious tech competitor to the US.

Stores of value. Assets that hold purchasing power amid inflation. and are top performers year-to-date. In a world of rising debt and inflation, scarcity matters. We believe this theme will remain valid in the years to come.

On behalf of the entire investment team at Syz Bank, we wish you a relaxing summer and a successful second half of the year – with many reasons to be cheerful along the way.

Most Popular

More from Author

Rhythm Pharma’s Oral Drug For Rare Obesity Shows Promise – Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals, Inc. RYTM on Wednesday released topline results from its...

Risk Assets Rebound as Trump Pushes Tariff Deadline to August 1

After a volatile past day session, this one was way calmer...

Markets Today: RBNZ Rate Hold, Copper Volatility, DAX Moves Toward Fresh Highs

Chinese stocks are set to hit their highest level in three...

Read Now

Rhythm Pharma’s Oral Drug For Rare Obesity Shows Promise – Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals, Inc. RYTM on Wednesday released topline results from its Phase 2 trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity.Hypothalamic obesity is a rare type of obesity resulting from damage to the hypothalamus, a brain region...

Risk Assets Rebound as Trump Pushes Tariff Deadline to August 1

After a volatile past day session, this one was way calmer as Trump announced yet another delay in tariff deadlines – From the approaching July 9th to August 1st, apparently the final warning. The session began with the leading to the upside, followed by general mean-reversion all...

Gilead’s Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million – Gilead Sciences (NASDAQ:GILD)

Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead’s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (PrEP).Through the agreement, Gilead will supply enough...

Markets Today: RBNZ Rate Hold, Copper Volatility, DAX Moves Toward Fresh Highs

Chinese stocks are set to hit their highest level in three years as investors hope for new steps to fight deflation and boost the economy. Meanwhile, dropped in London after President Donald Trump issued a new tariff warning.Asian Market WrapThe Shanghai Stock Exchange Composite Index rose...

FDA Approves New Dosing Schedule For Eli Lilly’s Kisunla In Alzheimer’s Treatment – Eli Lilly (NYSE:LLY)

The U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Eli Lilly and Co.’s LLY Kisunla (donanemab-azbt) once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer’s disease (AD). The FDA approved the drug in July 2024.In the TRAILBLAZER-ALZ 6...

Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug – Merck & Co (NYSE:MRK), Verona Pharma (NASDAQ:VRNA)

Merck & Co. Inc. MRK agreed on Wednesday to acquire Verona Pharma plc VRNA for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents eight ordinary shares of Verona Pharma.Through the acquisition of this respiratory disease-focused company, Merck...

The Energy Report: Demand Exceeding Supply

It’s the oldest story in the book. Prices go up when demand exceeds supply, not only in oil and products but in wholesale power, driving up electricity costs. The Energy Information Administration (EIA) in its Short-Term Energy Outlook confirmed that we have a global supply deficit. Not only...

Altcoin Rotation Gains Steam as Bitcoin and Ethereum Take a Backseat

Despite increasing trade tensions and tariff worries, crypto continues to hold up. More than that, the group is actually performing pretty well. is leaning on a potential breakout, but it’s not doing the heavy lifting right now. To some extent, neither is . Instead, it’s more broad. Stellar,...

DAX Pushes Higher as EU Edges Closer to Tariff Deal With US

rises as investors await trade news from Trump. shows resilience despite a rise in inventories and uncertainty over trade tariffs. The DAX, along with European indices, is inching higher on Wednesday, supported by defence stocks as investors wait for news on a trade deal with the...

Oil Prices Near 2-Week Highs on OPEC+ Output and US Tariffs

climbed Tuesday, hovering near two-week highs as markets absorbed the impact of a larger-than-expected OPEC+ production increase and ongoing uncertainty around US trade policy. As of mid-afternoon, was up 89 cents at $70.47 per barrel, while US West Texas Intermediate rose 80 cents to $68.73. Both...

Oil: Can the Market Absorb OPEC+ Output Hikes?

OPEC+ surprised markets by announcing a larger-than-expected August output hike of 548,000 bpd. Analysts say actual supply increases remain limited due to ongoing compensation cuts. Strong summer demand, especially from Asia, is expected to absorb the added barrels, but demand could falter this autumn. OPEC+ never fails to surprise speculators...

US Dollar Fights an Uphill Battle Amidst Mounting Tariff Pressure

More Trump letters to be sent, with copper, chips, and pharma next on the tariff list Dollar struggles to hold recent gains, except versus the yen US equities are on the back foot, underperforming their European counterparts RBNZ stands pat; Antipodeans post small gains against the greenback Dollar Is Swimming UpstreamThe...